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Myelination Processes Increase Postpartum
Psychosis Risk?Paola Dazzan,1,2 Montserrat Fusté,1 and William Davies3,*Highlights
Postpartum psychosis (PP) is a rare,
severe psychiatric disorder affecting
some women shortly after childbirth.
While the risk factors for PP are rela-
tively well understood, our knowledge
of the underlying pathophysiology is
extremely poor; however, there is
some evidence that immune system
dysregulation may play a role.
A recent study has shown that regu-
latory T cells (Tregs) may promote
remyelination via the CCN family ofPostpartum (or puerperal) psychosis (PP) is a rare, severe psychiatric disorder
that affects women shortly after childbirth; risk is particularly high in individuals
with a history of bipolar disorder or PP, but the underlying pathophysiology
remains poorly understood. Emerging evidence suggests that immune system
(dys)function plays an important role in disorder onset. On the basis of new
ﬁndings from clinical and animal model studies, we hypothesise that the
abundance and/or activity of regulatory T cells, and the efﬁcacy of consequent
(re)myelination processes in the brain mediated by CCN proteins, is perturbed
in PP; this pathway may be modulated by risk and protective/treatment factors
for the disorder, and identifying abnormalities within it could signpost novel
predictive biomarkers and therapeutic targets.proteins.
Here, we argue, on the basis of emer-
ging immunological, animal model,
and neuroimaging ﬁndings, that PP
risk may be elevated due to abnorm-
alities in the Treg–CCN–(re)myelination
axis and that risk and protective/treat-
ment factors for the disorder may inﬂu-
ence this axis.
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Postpartum psychosis (PP) is a severe psychiatric disorder affecting approximately one or
two of every 1000 women shortly after childbirth (most often within 6 weeks); the main
symptoms include hallucinations, delusions, cognitive disorganisation, and mood abnormali-
ties [1]. PP risk is highly predictable, with a risk recently reported to be 35% for women with
a history of either bipolar affective disorder or previous PP [2]. Although PP occurs concomi-
tantly with the biological sequelae of childbirth, its neurobiological basis remains poorly
understood.
The most intensively studied biological changes in PP have been those that occur in maternal
reproductive hormones shortly after childbirth; however, no differences in absolute levels of
oestrogen or progesterone have been identiﬁed in women who develop an episode of PP [3,4].
A genetic liability to PP has also been suggested: a linkage study in women with bipolar affective
PP implicated chromosomal regions 16p13 and 8q24 (regions previously associated with
bipolar disorder vulnerability) [5], while genetic association studies have provided suggestive,
albeit inconclusive, evidence of risk variants within candidate genes involved in serotonergic,
hormone-dependent, or stress-response pathways [6–8].
Key obstacles in identifying biological risk and protective factors for PP include low disorder
prevalence, high between-patient symptom heterogeneity, lack of accessibility to patient brain
tissue, and a historical lack of amenable model systems [9]. However, understanding the
pathophysiology of PP is crucial for identifying both novel therapeutic targets (for more
efﬁcacious drugs with fewer adverse effects) and predictive biomarkers (for identiﬁcation of
the most ‘at risk’ women before, or during, pregnancy, thereby facilitating earlier, more
individualised clinical interventions).Trends in Molecular Medicine, Month Year, Vol. xx, No. yy https://doi.org/10.1016/j.molmed.2018.09.002 1
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Glossary
CCN protein family: the CCN family
of proteins comprise six members,
with the CCN abbreviation deriving
from the ﬁrst letters of the ﬁrst three
family members: CYR61 (CCN1),
CTGF (CCN2), NOV (CCN3), WISP1
(CCN4), WISP2 (CCN5), and WISP3
(CCN6). CCN proteins are expressed
both within the cell and in the
extracellular matrix. They mediate a
wide range of fundamental cellular
processes including survival,
proliferation, differentiation,
senescence, adhesion, and
migration.
Oligodendrocytes:
oligodendrocytes are central nervous
system cells, the primary function of
which is to provide support and
insulation to axons through forming a
myelin sheath. In the adult brain,
oligodendrocytes develop from
oligodendrocyte progenitor cells.
Regulatory T cells: regulatory T
cells are a subpopulation of the
immune system’s T cell ensemble.
They are immunosuppressive and act
to ‘dampen’ the activity of effector T
cells, thereby helping to maintain
tolerance to self-antigens and
prevent autoimmune conditions.Recent evidence has highlighted a potentially important role for the immune system in the onset
of PP: women with the disorder have higher rates of autoimmune thyroid dysfunction and pre-
eclampsia (considered a disease of immunological maternal-fetal incompatibility) [1,10], and
some cases of PP involve an autoimmune response against the N-methyl-D-aspartic acid
receptor [11]. The link between PP pathophysiology and the immune system may not be
surprising, given that immune system dysregulation, characterised by elevated levels of serum
proinﬂammatory cytokines such as interleukin (IL)-6, IL-1, and tumour necrosis factor-a, and
alterations in the expression of associated genes now features prominently in pathophysiologi-
cal models of depression (including in the postpartum period) [12,13], bipolar affective disorder
[14], and psychosis [15,16].
Immune System Dysfunction and PP
PP occurs at a time of naturally heightened immune responsiveness. In pregnancy, a predomi-
nant anti-inﬂammatory T helper (Th)2-type immunity (whereby Th2 cell activity, including
cytokine expression, is favoured over that from Th1 cells), has been historically considered
responsible for maternal tolerance toward fetal alloantigens to protect the foetus from maternal
Th1 cell-mediated immunity and subsequent attack [17]. However, more recent models of
immunity function in pregnancy also implicate other T cell types, including regulatory T cells
(Tregs; see Glossary), cytotoxic natural killer (NK) cells, and Th17 cells [18,19]. Treg levels
typically increase in late pregnancy and peak early in the postpartum period, to be followed by
later depletion [19]. Not only may Treg cells be important for regulating immunity and mediating
self-tolerance in pregnancy but also for moderating the course of autoimmune disorders during
this period. For example, the proliferation of Tregs that occurs during pregnancy is thought to
mitigate acute exacerbations of multiple sclerosis (MS), an immune system-mediated demye-
linating disease [20].
Two recent studies have reported that women with PP have lower levels of Th1, Th17, and
Tregs [21] and a lower proportion of naïve Tregs (but a higher proportion of memory Tregs) [22]
than healthy postpartum women. These ﬁndings may reﬂect the disrupted function of one or
more subpopulations of Tregs in this clinical group, although the mechanisms underlying group
differences in T cell proportions, and their precise functional relevance, are currently unclear. In
addition, women with PP have been reported to exhibit lower numbers of NK cells [21] but
increased regulatory NK cells [22] that counterbalance the cytotoxic NK response and are
suggestive of a possible defect in the immune restoration normally present in the postpartum
period. Furthermore, women with PP show a reduction in numbers of dendritic cells [22]; these
cells are known to secrete higher levels of IL-12 and IL-6 in MS by inducing proinﬂammatory
Th1 and Th17 cells, and their reduced numbers in women with PP could theoretically result in
the persistence of immunosuppressive cells in the postpartum period.
Finally, monocyte and macrophage levels have also been found to be signiﬁcantly higher in
women with PP than in those without PP. Although Kumar and colleagues [22] found no
difference in total monocyte numbers between women with PP and healthy postpartum
women, their study did ﬁnd lower levels of the non-classical monocyte subtype, which display
inﬂammatory characteristics upon activation, in the former group. The parallel ﬁndings of higher
blood levels of chemokine CCL2 (produced by monocytes during tissue inﬁltration) in women
with PP, and of a robustly upregulated immune system-related gene expression proﬁle in this
clinical group, strongly support the relevance of monocyte alterations in this disorder [21].
Collectively, the above-mentioned data support a model for PP whereby an imbalance between
proinﬂammatory and immunosuppressive cells of the immune system in the postpartum period2 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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to be established whether, and how, peripheral immune activation might affect the maternal
brain processes that underlie PP onset. However, data relevant to the pathophysiology of MS
and other psychiatric conditions, discussed in the subsequent sections, suggest that an
inﬂuence on myelination processes is possible.
Myelination Processes in the Perinatal Period
While gray and white matter abnormalities have been consistently reported in psychoses not
related to the puerperium [23], until very recently, brain structure had never been investigated in
PP. To date, only one study (from our group) has systematically evaluated gray matter structure
using magnetic resonance imaging in women at risk of PP [24]. In brief, this study found that ‘at
risk’ women who developed PP had smaller volumes of the anterior cingulate, superior
temporal, and parahippocampal gyri compared to women at risk who did not develop PP,
a pattern of alterations resembling that often found in patients with psychoses not related to the
puerperium. Using a different imaging sequence, we also showed in this sample that women at
risk of PP have reduced myelin content in the temporal lobes and sublobar areas relative to
healthy women [25]. A case report in which PP was associated with white matter pathology in
the corpus callosum [26] adds further weight to a possible link between PP risk and abnormal
myelination processes.
Studying white matter structure using sufﬁciently sensitive methods may be particularly infor-
mative in the context of PP, given evidence that maternal brain structure and associated
physiology change substantially during pregnancy and into the postpartum period [27,28] and
that there are notable sex differences in white matter structure, both in healthy individuals and in
those affected by psychosis [29,30]. Of relevance to our proposed model, pregnancy is a time
of considerable change in women with MS and in animal models of the condition, whereby
symptom severity and the number/size of active white matter lesions are reduced [31]; this may
be explained by the hormonal changes that physiologically occur in pregnancy (notably
changes in prolactin levels), which can stimulate the maternal central nervous system
(CNS) to generate new myelinating oligodendrocytes and facilitate partial remyelination,
even in the presence of immune activation [32]. We propose that the (re)myelination processes
that occur during pregnancy and the postpartum period in MS patients (and possibly also in
healthy individuals) are compromised in women at risk of PP; this may explain why bipolar
disorder symptoms do not improve signiﬁcantly during pregnancy [33,34].
A New Hypothesis Reconciling Immune System Dysfunction and Myelination
Abnormalities in PP
The recent publication of a study examining the cellular and molecular underpinnings of MS
prompted us to consider previously unexplored mechanisms that may contribute to PP
vulnerability. This new study elegantly demonstrated that Tregs can promote oligodendrocyte
differentiation and (re)myelination within the CNS independently of inﬂammatory processes via
secretion of the protein CCN3 (also known as nephroblastoma-overexpressed protein, or NOV)
[35]. This ﬁnding was of particular interest to us given that the CCN protein family member
CCN3 had been suggested as a candidate mediator of PP risk by our work in a novel
pharmacological mouse model [36]. In our model, Ccn3 expression was upregulated in whole
brain tissue from new mouse mothers acutely administered an inhibitor of steroid sulfatase (to
mimic the putative PP risk factor maternal steroid sulfatase deﬁciency [37]); these mice
exhibited abnormal postpartum anxiety-related and startle behaviours of possible relevance
to PP. The behavioural abnormalities and the Ccn3 overexpression in the mouse model couldTrends in Molecular Medicine, Month Year, Vol. xx, No. yy 3
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and predictive validity. The ﬁnding that manipulation of placental gene activity in mice gives rise
to altered maternal behaviours and increased brain (hippocampal) Ccn3 expression [38] further
supports the notion of CCN3 as a mediator of postpartum psychopathology [9,36].
Our pharmacological model also revealed increased brain gene expression for putative CCN
protein interactors, including the pro-depressant CCN2(CTGF) [39], which may heterodimerise
with CCN3 and exert antagonistic effects [40], and the PP-relevant CCL2 protein [36,41].
CCN2 blocks oligodendrocyte differentiation to reduce myelination levels [42,43] while CCL2
(monocyte chemoattractant protein-1) can inﬂuence blood–brain barrier permeability [44] and
mobilisation of oligodendrocyte progenitor cells [45].
The CCN3 protein is present in the extracellular matrix, the cytoplasm, and the nucleus, and is
involved in many diverse cellular processes including cell adhesion, migration, proliferation,
differentiation, and survival [46]; it possesses multiple functional characteristics that support its
candidacy as a mediator of PP risk, and its associated gene is located within the candidate PP
genetic risk locus at 8q24 [9,36]. In adult human brain, CCN gene family members, including
CCN3, are highly expressed throughout the cortex and the limbic system [46], and their
expression in these, and other tissues, may be modulated by several PP-relevant molecules
such as oestrogen, serotonin, cytokines, psychotomimetics, and the mood-stabilising drug
lithium [9,36].
The intriguing ﬁndings described above, together with emerging knowledge of immune system
and brain structural alterations in PP, have allowed us to generate a novel and testable
evidence-based hypothesis regarding PP risk that reconciles these lines of evidence. Generally,
we propose that women at risk of PP are more likely than healthy individuals to display
abnormalities in the immune system–CCN family (and interactors)–(re)myelination axis and
that disruption of this axis is a core pathophysiological feature of PP. Speciﬁcally, we propose
that a perturbation in Treg abundance/activity in women at risk of PP may be associated with
altered expression of the CCN3 protein in the brain and subsequently with reduced levels of
myelination in cortical and limbic brain regions exhibiting the highest CCN3 expression and/or
with the greatest accessibility to Treg inﬂux.
Modulation of the Treg–CCN3–Myelin Axis by Risk and Protective/Treatment
Factors for PP
If dysfunction of the aforementioned axis contributes signiﬁcantly to PP pathophysiology, we
might expect key risk and protective factors associated with the condition to impact upon it.
Patients with bipolar disorder show consistent evidence for reduced numbers of circulating
Tregs [47,48], and this is correlated with white matter integrity across much of the brain [49]; the
molecular mechanisms underlying this correlation are, as yet, undetermined. Similarly, patients
with autoimmune thyroid diseases have been reported to exhibit reduced Treg numbers [50] or
impaired Treg cell function [51]. There is convincing evidence that the thyroid system can affect
myelination and neural connectivity processes [52], and rodent work has demonstrated that
CCN expression is regulated by the thyroid hormone triiodothyronine in brain cortex [53]. Pre-
eclampsia is also associated with low levels of circulating Tregs in some cases [54], with long-
term white matter changes (notably in the temporal lobe, an area involved in the pathophysiol-
ogy of psychosis [55,56]), and with perturbed expression of CCN family members (including
CCN3) in placental tissue and serum [57]. Moreover, CCN3 has repeatedly been implicated as
a risk factor for hypertension [58], a core feature of pre-eclampsia.4 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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been reported to be lower in women with PP than in healthy controls [60], and reduced
kynurenine levels in patients with bipolar disorder have been associated with impaired white
matter integrity [61]. Furthermore, the fact that remyelination efﬁciency decreases with age [62]
may feasibly explain the association between PP risk and older maternal age [63].
Mood-stabilising drugs such as lithium have been reported to enhance white matter integrity in
adults with bipolar disorder [64,65], most likely through stimulating (re)myelination-promoting
molecular cascades in oligodendrocytes [66]. The effects of antipsychotic administration on white
matter integrity appear inconsistent and are more poorly deﬁned, but there is some evidence for
enhanced myelination via effects on oligodendrocytes [67,68]. Finally, rates of PP are higher in
non-smokers than in smokers with bipolar disorder [69]; this is interesting since smoking boosts
numbers and/or functionofTregs in the largeairways and lungs (andpossibly other tissues) [70,71]
and reduces Ccn3 expression in these tissues in a model system [72].
Limitations of the Hypothesis
Some important limitations to this proposed new hypothesis should be considered. First, the
immunological, neuroimaging, and animal model ﬁndings upon which the hypothesis is
founded are provisional and have yet to be replicated and fully characterised. Moreover, to
date, it has been challenging to examine links between subtly aberrant de- or remyelination
processes and vulnerability to general psychoses due to technical and practical limitations; with
the advent of techniques with improved reliability and sensitivity, it should be possible to
address more effectively how the former might inﬂuence the latter [73]. Second, other studies in
women with PP or using alternative experimental models have not yet provided evidence for our
hypothesis, although they have not refuted it. For example, early results from genome-wide
association studies in PP have not identiﬁed dysfunctional T cell, CCN-related, or myelination
pathways; however, this ‘absence of evidence’ should be viewed in light of the fact that these
genetic studies are currently signiﬁcantly underpowered [9]. Similarly, genetic and gene
expression data from another animal model for PP, the infanticidal sow pig, have not strongly
highlighted these pathways, although altered brain expression of myelin basic protein (MBP),
prolactin, and the antipsychotic-target dopamine receptor D2 was noted in this model [74]; this
lack of convergence could be explained by the fact that gene expression was only examined in
a single brain region (the hypothalamus) involved in maternal behaviour, but not yet strongly
implicated in PP pathophysiology [9]. An association analysis in the infanticidal sow pig
highlighted PAX3 as a candidate gene [75]; PAX3 may act as a transcriptional activator or
repressor at the CCN3 [76] and MBP [77] genes, respectively.
Third, our hypothesis does not deﬁnitively identify the ‘postpartum trigger’. In a diathesis model,
it is possible that dysregulation of the Treg–CCN3–myelination pathway confers trait vulnera-
bility to PP and that the disorder then becomes manifest upon exposure to postpartum-speciﬁc
factors, such as changes in hormone levels or environmental stressors. Alternatively, as studies
aimed at understanding the molecular pathogenesis of bipolar disorder have not yet implicated
CCN3 abnormalities, and as brain levels of CCN family proteins (and interactors) ﬂuctuate
considerably across mammalian pregnancy and the postpartum period [78], it is plausible that it
is speciﬁc abnormalities in the expression/function of these proteins that confer PP risk.
Finally, it is unclear how Tregs may mediate myelination processes in the brain in women at risk,
or with a history, of PP. Theoretically, this could be via secretion of factors such as CCN3 into
the peripheral circulation and subsequent uptake into the brain. Alternatively, Tregs may
percolate into the brain via a permeabilised blood–brain barrier (perhaps facilitated by increasedTrends in Molecular Medicine, Month Year, Vol. xx, No. yy 5
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Clinician’s Corner
Postpartum psychosis (PP) is a rare,
severe, psychiatric disorder affecting
some women shortly after childbirth;
risk is known to be substantially ele-
vated in women with a previous history
of bipolar disorder, schizoaffective dis-
order, or PP, but the underlying patho-
physiology is extremely poorly
understood. Moreover, approximately
half of the time, PP occurs in women
with no previous psychiatric history.
While the current treatments for PP are
relatively efﬁcacious, they do not target
the cause of the disorder, they may be
teratogenic if administered prophylac-
tically during pregnancy, and they may
have adverse side effects. There are
currently no predictive markers avail-
able for PP; such markers would allow
women at high risk to be identiﬁed
early in pregnancy, thereby facilitating
earlier, more individualised, and more
effective clinical intervention.
Here, we hypothesise, based upon
emerging immunological, animal
model, and neuroimaging data, that
PP risk may be mediated by dysfunc-
tion of the regulatory T cell–CCN pro-
tein family–(re)myelination axis, a
pathway that is also potentially aber-
rant in multiple sclerosis (MS); hence,
we suggest that increased collabora-
tion between clinicians and basic sci-
entists studying PP and MS is
warranted.
The identiﬁcation of abnormalities
within the axis above in women at high
risk of PP could ultimately allow the
development of predictive biomarkers
and more targeted treatment options
with fewer side effects for this vulnera-
ble group.
Outstanding Questions
How do regulatory T cell (sub)popula-
tions differ between women who have
experienced an episode of postpartum
psychosis (or who are at high risk) and
mothers who have not?
Does the sequence of CCN2, CCN3,
and DDR1 genes differ between
women who have experienced an epi-
sode of postpartum psychosis (or who
are at high risk) and mothers who have
not?CCL2 expression) and/or via the choroid plexus to affect function in the nearby limbic system
[79]. While there is some evidence that Treg inﬁltration into the CNS may inﬂuence the
presentation of MS (and possibly also bipolar disorder) [49,79], to date there is no published
information on the integrity of the blood–brain barrier in women with PP.
Concluding Remarks
The precise mechanistic details by which Tregs might permeate the CNS, produce and secrete
CCN3, and by which CCN3 may then inﬂuence oligodendrocyte-mediated (re)myelination
processes remain to be clariﬁed over the coming years. Identifying the effectors of these
processes would allow a more focussed genetic, biochemical, and cellular investigation of the
pathophysiology of PP. For example, genetic studies might focus upon speciﬁc candidate
genes or pathways that are highlighted, negating the need for genome-wide multiple testing
correction. A putative interactor with CCN3, discoidin domain receptor 1 (DDR1) [80], may
warrant further analysis in PP: intriguingly, this gene/protein is highly expressed in human CNS
myelin where it co-localises with MBP [81], is upregulated during oligodendrocyte-mediated (re)
myelination [82], and is associated with psychotic illness [83]. In the shorter term, clinical studies
in women at risk of, or with, PP might focus on evaluating the number, proportion, and subtype
of circulating Tregs; the frequency of genetic variants within CCN family and DDR1 genes; levels
of CCN3 (and CCN2) gene/protein expression in peripheral tissues such as serum, cerebro-
spinal ﬂuid, and urine during pregnancy and the postpartum period; and the degree/integrity of
myelination in relevant limbic and cortical structures.
Our hypothesis may also be tested in more experimentally tractable systems, such as rodent
models in which detailed measures of myelination can be obtained in vivo or postmortem using
imaging and/or histological methods, respectively. In adult mice, Treg depletion in combination
with exposure to environmental stressors results in phenotypes of relevance to PP (notably
increased anxiety-related behaviours) together with decreased hippocampal serotonin levels
[84]. We predict that Treg depletion and stressor exposure should elicit differential effects on
maternal behaviour, Ccn3 expression, hippocampal 5-hydroxytryptamine, and myelination levels
in postpartum versus non-postpartum female mice, and versus control postpartum mice. Finally,
gross manipulation of CCN3 levels in vivo (e.g., in knockout mice or in brain-overexpression
models) or in vitro in mixed neuron–oligodendrocyte cell cultures may be associated with
perturbed myelination and corresponding PP-relevant behavioural phenotypes. Likewise, in
the pharmacological and genetic mouse models that display abnormal maternal behaviour
and altered Ccn3 expression [9,36,38], we might expect subtle changes in myelination markers.
We believe that the hypothesis described above provides a plausible and coherent central risk
mechanism for PP, drawing together existing lines of evidence implicating risk and protective/
treatment factors. The hypothesis makes speciﬁc and testable predictions across many clinical
and experimental systems (see Outstanding Questions). Conﬁrmation of abnormalities in the
Treg–CCN3–myelin axis in PP might feasibly identify new avenues of treatment for PP (e.g., via
modulation of Treg number/function [85] or CCN3 knockdown [86]), as well as novel predictive
peripheral biomarkers (e.g., genetic polymorphisms, or perturbed peripheral CCN levels).
Finally, our idea suggests that not only studies in inﬂammatory and autoimmune conditions
previously associated with PP (e.g., pre-eclampsia and thyroid disorders) but also studies
investigating immune conditions associated with aberrant (re)myelination and neuropsychiatric
phenotypes such as MS might be informative for understanding PP pathophysiology; as such,
a greater degree of collaboration between clinicians and scientists working within these areas is
warranted.6 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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Does the peripheral expression of
CCN2, CCN3, and DDR1 genes (and
their associated proteins) differ
between women who have experi-
enced an episode of postpartum psy-
chosis (or who are at high risk) and
mothers who have not?
Do markers of (re)myelination efﬁcacy
differ between women who have expe-Acknowledgements
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